Transporter-14 Mission: SpaceX To Launch Capsules Of DNA, Human Remains Into Space
The samples will be onboard the Perseverance Flight, which is a project by Celestis, a Houston-based company, that offers a unique way to honour loved ones. The Perseverance Flight will carry more than 150 capsules with samples.
The company said that after reaching space, the capsules will return to Earth aboard their recovery vehicle. The memorial capsules will land safely in the Pacific Ocean, where they will be recovered and returned to the family as a "lasting tribute" to their loved one's journey among the stars.
The flight will travel at 17,000 miles per hour and achieve Low Earth Orbit after its launch from the Vandenberg Space Force Base in California. It will complete two to three full orbits around Earth before gently re-entering the atmosphere.
The development highlights the trend of space burial, which has happened in the past. Gene Roddenberry, creator of Star Trek, was the first person to have his remains buried in space in 1992. Eugene Merle Shoemaker, a renowned astronaut, was the first person to have his remains buried on the Moon. Timothy Leary, a psychologist and philosopher, also had his remains launched into space.
In an X post, SpaceX updated that the launch date was changed from Sunday to Monday due to unfavourable weather.
Due to unfavorable weather, now targeting Monday, June 23 for launch of the Transporter-14 mission from California → https://t.co/dZHlwDDeMS
— SpaceX (@SpaceX) June 22, 2025
Celestis announced that it has entered into a new launch service in collaboration with The Exploration Company (TEC) - a European spacecraft manufacturer.
"Celestis is pleased to offer a new type of Earth Rise mission, thanks to The Exploration Company," Charles Chafer, the company's co-founder and CEO, said in a statement. "Our participants' capsules will orbit the Earth and return via the Mission Possible capsule, creating a spectacular liftoff and recovery experience."
What is space burial, and what are the common methods to do it?
The space burial is a unique way to honour the loved ones by launching cremated remains into space.
Earth Orbit: Remains are launched into orbit around the Earth, where they stay for some time before burning up upon re-entry.
Moon Burial: Remains are taken to the lunar surface, providing a lasting tribute.
Deep Space: Remains are launched into deep space, travelling beyond the solar system.
Suborbital Flights: Short flights that cross the boundary of space without reaching orbital velocity, often returning to Earth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
6 minutes ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
36 minutes ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
an hour ago
- Time of India
Urgent need for 'global approach' on AI regulation: UN tech chief
Geneva: The world urgently needs to find a global approach on regulating artificial intelligence, the United Nations ' top tech chief said this week, warning that fragmentation could deepen risks and inequalities. Doreen Bogdan-Martin , head of the UN's International Telecommunications Union ( ITU ) agency, told AFP she hoped that AI "can actually benefit humanity". But as concerns mount over the risks posed by the fast-moving technology -- including fears of mass job losses, the spread of deepfakes and disinformation, and society's fabric fraying -- she insisted that regulation was key. "There's an urgency to try to get... the right framework in place," she said, stressing the need for "a global approach". Her comments came after US President Donald Trump this week unveiled an aggressive, low-regulation strategy aimed at ensuring the United States stays ahead of China on AI. Among more than 90 proposals, Trump's plan calls for sweeping deregulation, with the administration promising to "remove red tape and onerous regulation" that could hinder private sector AI development. Asked if she had concerns about an approach that urges less, not more, regulation of AI technologies, Bogdan-Martin refrained from commenting, saying she was "still trying to digest" the US plan. 'Critical' "I think there are different approaches," she said. "We have the EU approach. We have the Chinese approach. Now we're seeing the US approach. I think what's needed is for those approaches to dialogue," she said. At the same time, she highlighted that "85 percent of countries don't yet have AI policies or strategies". A consistent theme among those strategies that do exist is the focus on innovation, capacity building and infrastructure investments, Bogdan-Martin said. "But where I think the debate still needs to happen at a global level is trying to figure out how much regulation, how little regulation, is needed," she said. Bogdan-Martin, who grew up in New Jersey and has spent most of her more than three-decade career at the ITU, insisted the Geneva-based telecoms agency that sets standards for new technologies was well-placed to help facilitate much-needed dialogue on the issue. "The need for a global approach I think is critical," she said, cautioning that "fragmented approaches will not help serve and reach all". As countries and companies sprint to cement their dominance in the booming sector, there are concerns that precautions could be thrown to the wind -- and that those who lose the race or do not have the capacity to participate will be left behind. 'Huge gap' The ITU chief hailed "mind-blowing" advances within artificial intelligence, with the potential to improve everything from education to agriculture to health care -- but insisted the benefits must be shared. Without a concerted effort, there is a risk that AI will end up standing for "advancing inequalities", she warned, cautioning against deepening an already dire digital divide worldwide. "We have 2.6 billion people that have no access to the internet, which means they have no access to artificial intelligence", Bogdan-Martin pointed out. "We have to tackle those divides if we're actually going to have something that is beneficial to all of humanity." Bogdan-Martin, the first woman to serve as ITU secretary-general in the organisation's nearly 160-year history, also stressed the need to get more women into the digital space. "We have a huge gap," she said. "We definitely don't have enough women... in artificial intelligence." The 58-year-old mother of four said it was "a big honour" to be the first woman in her position, to be "breaking the glass ceiling (and) paving the path for future generations". But she acknowledged there was a lot of pressure, "not just to achieve, but to almost overachieve". Bogdan-Martin, who is being backed by the Trump administration to stand for re-election when her four-year mandate ends next year, said she was eager to stay on for a second term. "There is a lot to do."
